SCM
ORKA

Silverarc Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Silverarc Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.4M Buy
+150,908
New +$5.24M 0.76% 35
2025
Q3 		– Sell
-165,389
Closed -$1.85M – 98
2025
Q2 		$1.85M Buy
+165,389
New +$1.72M 0.34% 46

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Silverarc Capital Management's ORKA Position: Q1 2026 in Review

Silverarc Capital Management opened a new position in Oruka Therapeutics (ORKA) in Q1 2026: 150,908 shares worth $7.4M. The stake represents 0.76% of the portfolio and ranks #35 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in ORKA as recently as Q2 2025.

Silverarc Capital Management first reported a position in ORKA in Q2 2025 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Silverarc Capital Management held 150,908 shares of Oruka Therapeutics worth $7.4M as of Q1 2026.
  • Oruka Therapeutics was a new Silverarc Capital Management position in Q1 2026.
  • Oruka Therapeutics made up 0.76% of Silverarc Capital Management's portfolio in Q1 2026, its #35 holding.
  • Silverarc Capital Management first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.